New York, NY — November 13, 2025
Biolux Technology, the global leader in light-based orthodontic innovation and maker of OrthoPulse®, today announced the appointment of Chuck Abraham as Chief Executive Officer, effective immediately.
Marcel Pordes, who has successfully led Biolux through its commercialization phase and the re-introduction of OrthoPulse in the United States, will transition into the role of Executive Director, focusing on strategic partnerships, product innovation, and corporate development.
This leadership transition marks an important milestone as Biolux strengthens its presence and operations in the U.S. market, which has become the company’s primary growth engine. Michael Hendricks will continue to lead U.S. business development and commercial strategy, reporting to Chuck Abraham — marking a new era of expansion and clinical adoption for OrthoPulse in the United States.
We are entering an exciting phase for Biolux,” said Chuck Abraham, CEO of Biolux Technology. “The U.S. orthodontic community is rapidly embracing OrthoPulse as the new standard for biologically optimized treatment. Our priority is to build a strong commercial foundation in the United States — expanding access, supporting our doctors, and demonstrating the clinical and business value of integrating near-infrared therapy into everyday orthodontic care.
Focused Leadership for U.S. Growth
Abraham, an experienced healthcare and medical device executive, brings a proven record of scaling innovative health technologies in competitive markets. His leadership will focus on accelerating Biolux’s commercial rollout, expanding practice adoption, and strengthening the company’s U.S. operations, including sales, clinical education, and digital engagement.
The U.S. market represents a tremendous opportunity for Biolux,” said Marcel Pordes, Executive Director of Biolux Technology. “With OrthoPulse gaining strong traction among leading orthodontic practices, Chuck’s experience and leadership will ensure that Biolux continues to scale effectively and deliver on its promise of transforming patient care.
The New Standard of Care in Orthodontics
OrthoPulse uses low-level near-infrared (NIR) light to stimulate the bone surrounding tooth roots, promoting natural bone remodeling and supporting more efficient, comfortable orthodontic treatment.
Clinically validated and FDA-cleared, OrthoPulse enhances both tooth movement and patient comfort — reducing discomfort, improving predictability, and minimizing refinements and chair time.
By delivering a faster, smoother, and more comfortable treatment experience, OrthoPulse is redefining what patients and professionals expect from modern orthodontic care.
We are committed to making OrthoPulse an integral part of every orthodontic treatment plan,” added Abraham. “Our goal is simple — empower U.S. orthodontists to achieve better results, faster, while giving patients a more comfortable treatment journey.
About Biolux Technology
Biolux Technology is a global leader in non-invasive light therapy devices for dental and orthodontic applications. Its flagship product, OrthoPulse, is FDA-cleared and CE-marked, supporting thousands of practices worldwide. Biolux is committed to advancing orthodontic care through innovation, data-driven platforms, and collaborative partnerships. Learn more: orthopulse.com
Media Contact: Michael Hendricks, Chief Business Officer at Biolux Technology USA LLC, m.hendricks@bioluxtec.com, 917-340-1651